Argen-X (ARGX)

368.50 +2.40 (+0.66%)
Real-time Data EUR Disclaimer

Argen-X Company Profile

Equity Type
argenx SE, formerly arGEN X BV, is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes: ARGX-110, an antibody for heme malignancies and solid tumors, which modulates functions of tumor such as cell proliferation and survival; ARGX-111, an antagonist of c-Met, a receptor tyrosine kinase involved in cell proliferation, angiogenesis and metastasis in multiple solid tumors; ARGX-112, an antigen which targets atopic dermatitis by neutralization of IL-20 and IL-22 (interleukin) mediated signaling through blockade of their common receptor, among others.
Contact Information
Breda,4811 AH Netherlands
31 10 703 8441
Top Executives
Peter K. M. Verhaeghe 64 2008 Independent Chairman of the Board
Timothy Van Hauwermeiren 50 2008 CEO & Executive Director
Werner Lanthaler 54 2014 Independent Vice-Chairperson
J. Donald deBethizy 72 2015 Independent Non-Executive Director
Pamela Klein 61 2016 Independent Non-Executive Director
James M. Daly 60 2018 Independent Non-Executive Director
Anthony A. Rosenberg 69 2017 Independent Non-Executive Director
Clear All
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.